Guardian Pharmacy Services Stock Market Outlook
| GRDN Stock | 37.24 0.60 1.64% |
When the sentiment score diverges from the price trend, it can highlight a disconnect between public perception and market action that merits a closer look. Around 54% of recent sentiment around Guardian Pharmacy has been mildly constructive over the recent sample. Taken on its own, that leaves the current sentiment reading for Guardian Pharmacy Services close to neutral at this time.
Investor Comfort Level
PanicConfidence
54 · Impartial
Elasticity to Hype and News Sentiment
At 50%, Guardian Pharmacy Services news tone is mixed, providing a perception layer that can precede fundamental repricing. That reading becomes more actionable when paired with valuation context and recent technical trend direction.
Given a 90-day horizon, with an above-average risk tolerance, the model output for Guardian Pharmacy Services is 'Strong Buy'. The Guardian Pharmacy buy-or-sell recommendation is derived from the selected investment horizon and risk tolerance parameters for Guardian Pharmacy.
Guardian |
Run Guardian Pharmacy Outlook Model
Our model-driven Guardian signal adds context to the existing analyst consensus on Guardian Pharmacy Services. Macroaxis maintains full independence and has no ownership position in Guardian Pharmacy Services. Guardian Pharmacy's outlook incorporates both technical signals and fundamental data points. Model-driven signals are most useful when they confirm or challenge existing views.
How This Model Works
The recommendation output for Guardian Pharmacy is a model-based view that converts the selected horizon and risk profile into a standardized reading of the current evidence.
- Inputs - valuation signals, price behavior, volatility, liquidity, sentiment, and analyst coverage when available
- Current setup - Three Months with a risk setting described as I am an educated risk taker
- Limits - the model does not account for taxes, outside holdings, concentration constraints, or investor-specific mandates
Use the output as structured decision support and pair it with your own research, portfolio context, and any professional advice you rely on.
Time Horizon
Risk Tolerance
Strong Buy
Market Performance | Moderate | Details | |
Volatility | Very Low | Details | |
Current Valuation | Below Model Estimate | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Guardian Pharmacy's current outlook reflects mixed signals, where recent market performance has undercut momentum, while contained volatility and intact fundamental quality provide partial offset. The model's 'Strong Buy' signal reflects this balance across quantitative inputs rather than a directional bias. Over the selected time horizon, Guardian Pharmacy shows Risk Adjusted Performance of 0.0953, Jensen Alpha of 0.2092, and Total Risk Alpha of 0.1928, which collectively support the constructive outlook.The Guardian Pharmacy quantitative signal draws on volatility, valuation, and earnings quality to produce a risk-aware signal that can be read alongside the analyst and expert consensus. For additional context on this mid-cap stock, evaluate the full set of Guardian Pharmacy reported fundamentals, including the relationship between the price to sales ttm and target price. Guardian Pharmacy reports a shares owned by insiders of 51.47 %. Its market performance and financial distress probability provide additional context.
Recent Events and Market Context
The events below reflect recent headlines associated with Guardian Pharmacy. Not all items directly affect the outlook — they are included to show the broader information environment that can shape sentiment and trading behavior.
Returns Distribution Density
The return distribution for Guardian Pharmacy shows how Guardian Pharmacy's daily price changes have varied. Returns near the center happen most often, while the edges show rare but large moves. Value At Risk pins down the downside, while Upside Potential pins down the upside. Combined with Value At Risk and Upside Potential, the expected performance range for Guardian Pharmacy's is framed.
| Mean Return | 0.23 | Value At Risk | -3.69 | Potential Upside | 3.58 | Standard Deviation | 2.47 |
Return Density |
| Distribution |
The return distribution chart for Guardian Pharmacy shows how often extreme price changes have occurred. The distribution of past returns provides that answer directly. It supports better-informed choices among risk-return profiles. Risk analysis for Guardian Pharmacy begins with the return distribution chart.
Key Drivers of Volatility and Market Exposure
Holders of Guardian Pharmacy face systematic risk from broad stock market trends and unsystematic risk from company or sector-specific developments. Diversification reduces specific exposure, but macro-driven volatility persists. Beta remains a common sensitivity metric. Latest disclosures for Guardian Pharmacy Services show a Downside Deviation of 2.57, a Mean Deviation of 1.85, and a Semi Deviation of 2.43.
α | Alpha over Dow Jones | 0.21 | |
β | Beta against Dow Jones | 0.89 | |
σ | Overall volatility | 2.47 | |
Ir | Information ratio | 0.08 |
Fundamentals Vs Peers
Guardian Pharmacy's fundamentals are most informative when placed alongside stocks of comparable size and structure. This peer-level view determines whether Guardian Pharmacy's current valuation multiple is justified by its relative operating performance. Fundamental peer comparison for Guardian Pharmacy contextualizes operating performance within the competitive landscape. Mispricing opportunities for Guardian Pharmacy become visible when key ratios diverge significantly from peer averages.
| Better Than Average | Worse Than Average | Compare Guardian Pharmacy to competition |
| Fundamentals | Guardian Pharmacy | Peer Average |
| Return On Equity TTM | 0.27 | -0.31 |
| Return On Asset TTM | 0.14 | -0.14 |
| Profit Margin TTM | 0.034 | -1.27 |
| Operating Margin TTM | 0.089 | -5.51 |
| Current Valuation | 2.38 B | 16.62 billion |
| Shares Outstanding | 37.28 M | 571.82 million |
| Shares Owned By Insiders | 51.47 % | 10.09 % |
| Shares Owned By Institutions | 59.35 % | 39.21 % |
| Number Of Shares Shorted | 2.52 M | 4.71 million |
| Price To Book TTM | 11.69 X | 9.51 X |
| Price To Sales TTM | 1.63 X | 11.42 X |
| Revenue TTM | 1.45 B | 9.43 billion |
| Gross Profit TTM | 292.72 M | 27.38 billion |
| EBITDA TTM | 111.25 M | 3.9 billion |
| Net Income TTM | 49.22 M | 570.98 million |
| Total Debt TTM | 44.72 M | 5.32 billion |
| Book Value Per Share TTM | 3.25 X | 1,931 |
| Cash Flow From Operations TTM | 100.29 M | 971.22 million |
| Short Ratio TTM | 3.77 X | 4.00 X |
| Earnings Per Share | 0.77 X | 3.12 X |
| Target Price | 40.83 | N/A |
| Number Of Employees | 3.6 K | 18,840 |
| Market Capitalization TTM | 2.36 B | 19.03 billion |
| Total Asset TTM | 412.66 M | 29.47 billion |
| Retained Earnings TTM | 66.34 M | 9.33 billion |
| Working Capital TTM | 60.93 M | 1.48 billion |
| Net Asset | 412.66 M | N/A |
Note: Insider Trading [view details]
Market Momentum
RSI at 52 (neutral) and beta of 0.8947 together frame Guardian Pharmacy Services momentum profile - showing how the stock is positioned relative to its own trend and the broader market. The business is commonly classified in the Healthcare sector and the Medical Care Facilities industry. Together, these momentum and sensitivity readings help investors judge whether a position adjustment or patience is warranted.
Recommendation Framework, Assumptions & Editorial Oversight
The model output for Guardian Pharmacy reflects the current horizon and risk settings, refreshes as underlying data changes, and is intended to organize evidence rather than replace investor judgment. Current model inputs for Guardian Pharmacy include ROE of 26.62%, market cap of 2.36 billion. 
Guardian Pharmacy Services metrics are compiled from periodic company reporting and market reference feeds and normalized before display. The model combines valuation, price behavior, volatility, and sentiment into a standardized quantitative view.
Editorial Review & Methodology Oversight
Role: Member of Macroaxis Editorial Board
Finance background: Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
Oversight scope: Reviews recommendation-framework framing, source assumptions, and disclosure language.